^
    3d
    Neoadjuvant Immunotherapy for Resectable Gastric Cancer (clinicaltrials.gov)
    P2, N=25, Completed, Qilu Hospital of Shandong University | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date • Combination therapy • IO biomarker • Metastases
    |
    KDR (Kinase insert domain receptor)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin
    7d
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    7d
    Design and Discovery of New Dual Carbonic Anhydrase IX and VEGFR-2 Inhibitors Based on the Benzenesulfonamide-Bearing 4-Thiazolidinones/2,4-Thiazolidinediones Scaffold. (PubMed, Drug Dev Res)
    All the target compounds were evaluated against CAIX enzyme compared to dorzolamide and acetazolamide, subsequently the most potent CAIX inhibitors (3a, 3b, 3o, 6d, 6g, and 6i) were selected to evaluate their inhibitory activity against VEGFR-2 using sorafenib as a reference drug. Physicochemical predictions were examined using in silico techniques. In conclusion, these scaffolds present promising leads and furnish promising chemical backbones for the design of potent dual CAIX and VEGFR-2 inhibitors.b.
    Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    sorafenib • acetazolamide
    9d
    APPEAL: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sun Yat-sen University | N=128 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement
    |
    carboplatin • AiTan (rivoceranib) • pemetrexed
    9d
    Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis (clinicaltrials.gov)
    P2, N=30, Recruiting, Beijing 302 Hospital | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Oct 2024
    Enrollment open • Trial initiation date
    |
    AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
    9d
    Establishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone. (PubMed, Hum Cell)
    However, doxorubicin, foretinib, and ceritinib were identified as promising therapeutic candidates due to their low IC50 values in NCC-GCTB10-C1. The establishment of NCC-GCTB10-C1 offers a critical resource for further research into GCTB, especially in the context of recurrent disease, and holds potential for the development of more effective treatment strategies.
    Preclinical • Journal
    |
    H3-3A (H3.3 Histone A)
    |
    doxorubicin hydrochloride • Zykadia (ceritinib) • foretinib (GSK1363089)
    15d
    Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy-case report. (PubMed, Front Oncol)
    After Oxaliplatin combined with S-1 regimen, the effect was up to PR...The combined application of S-1 and Apatinib in gastric cancer maintenance therapy deserves further study. Maintenance therapy for gastric cancer has attracted wide attention, and more large-scale clinical research is under way.
    Journal • Metastases
    |
    KDR (Kinase insert domain receptor)
    |
    AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    16d
    Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=31, Completed, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2022 --> Mar 2024 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    16d
    RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. (PubMed, J Thorac Oncol)
    In RELAY, OS was not significantly improved with similar long OS durations in both treatment arms.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • TP53 wild-type
    |
    Tagrisso (osimertinib) • erlotinib • Cyramza (ramucirumab)
    17d
    Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer. (PubMed, ESMO Open)
    Characterizing unresectable, metastatic, or recurrent GC with positive CLDN18.2 expression and evaluating intratumoral heterogeneity and prognostic implications of various therapeutics help advance treatment strategies and develop new therapies for patients with GC.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • HER-2 positive • CLDN18.2 expression • CLDN1 positive
    |
    VENTANA CLDN18 (43-14A) Assay
    |
    Herceptin (trastuzumab) • paclitaxel • Cyramza (ramucirumab)
    19d
    Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial. (PubMed, Nat Commun)
    The most common grade 3-4 treatment-related adverse events were alanine aminotransferase elevation, aspartate aminotransferase elevation, and lymphopenia. Predefined exploratory analyses indicated that patients with higher peripheral blood CXCR3 + CD8 + T cell abundance, lower immunosuppressive CD4 + T cell abundance, and higher overlap of clonotypes between tumor-infiltrating T cells and circulating T cells, were more likely to respond favorably to the combined therapy.
    P2 data • Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    20d
    S1701: Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, SWOG Cancer Research Network | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date • Surgery • Metastases
    |
    carboplatin • paclitaxel • Cyramza (ramucirumab)
    21d
    Enzyme (α-Glucosidase, α-Amylase, PTP1B & VEGFR-2) Inhibition and Cytotoxicity of Fluorinated Benzenesulfonic Ester Derivatives of the 5-Substituted 2-Hydroxy-3-nitroacetophenones. (PubMed, Int J Mol Sci)
    The results of an in vitro enzymatic study were augmented by molecular docking (in silico) analysis. Their ADME (absorption, distribution, metabolism and excretion) properties have been evaluated on the most active compounds against α-glucosidase and/or α-amylase to predict their drug likeness.
    Journal
    |
    KDR (Kinase insert domain receptor) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1)
    22d
    Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial (clinicaltrials.gov)
    P3, N=214, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    27d
    CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Eli Lilly and Company | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    28d
    New series of 4,6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR/VEGFR-2 inhibitors. (PubMed, Front Chem)
    The docking study showed that compounds 22 and 29 had docking scores similar to those of Erlotinib and Sorafenib, co-crystallized ligands, for the EGFR and VEGFR-2 proteins. The experiments on lipophilicity showed that the new pyrimidines had a consistent result. This group of compounds has better biological activity in all the biological systems studied with low lipophilicity.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    erlotinib • sorafenib
    28d
    Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC (clinicaltrials.gov)
    P2, N=188, Recruiting, The First Affiliated Hospital of Zhengzhou University | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Jul 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    30d
    Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. (PubMed, Lancet Oncol)
    Paclitaxel and ramucirumab switch maintenance could be a potential treatment strategy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer who are not eligible for immunotherapy or targeted agents.
    P3 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • 5-fluorouracil • capecitabine • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium
    30d
    First-line Treatment of Advanced/unresectable DDLPS (clinicaltrials.gov)
    P2, N=49, Not yet recruiting, Fudan University
    New P2 trial • Combination therapy • Metastases
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • pegylated liposomal doxorubicin
    1m
    MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Ruijin Hospital
    New P2 trial • Metastases
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    1m
    CDH2 and CDH13 as potential prognostic and therapeutic targets for adrenocortical carcinoma. (PubMed, Cancer Biol Ther)
    Foretinib and elesclomol were predicted to exert strong inhibitory effects on SW13 cells by inhibiting the expression of CDH2 and CDH13. These data indicate that CDH2 and CDH13 are promising targets for precise treatment of ACC and may serve as new biomarkers for ACC prognosis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CDH2 (Cadherin 2)
    |
    CDH1 expression
    |
    elesclomol (STA-4783) • foretinib (GSK1363089)
    1m
    Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers. (PubMed, Future Med Chem)
    Compound 16c boosted the level of the apoptotic caspase-3 and inhibited the level of TNF-α and IL-6 in tumor cells. Molecular docking and molecular dynamics (MD) simulations indicated the outstanding binding potential of compound 16c against VEGFR-2. Compound 16c is a good candidate for the creation of a novel antiangiogenic lead anticancer medication.
    Journal • Immunomodulating
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
    1m
    TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis. (PubMed, Cell Death Dis)
    The combined application of ERK inhibitors, U0126 or trametinib, with the VEGFR inhibitor Apatinib, additively suppresses angiogenesis and tumor growth of HCC1806 in nude mice. These findings provide new therapeutic strategies for TNBC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Mekinist (trametinib) • AiTan (rivoceranib)
    1m
    Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report. (PubMed, Medicine (Baltimore))
    This case highlights the potential antitumor activity of apatinib in breast cancer patients with presenting with PLC. While further studies are necessary, this therapeutic approach could represent a viable option for managing breast cancer in the context of a visceral crisis. The case also emphasizes the importance of individualized treatment strategies and further research to substantiate these promising findings.
    Journal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel
    1m
    A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=16 --> 0 | Trial completion date: Nov 2028 --> Nov 2024 | Initiation date: Apr 2025 --> Nov 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Nov 2024
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Metastases
    |
    AiTan (rivoceranib)
    1m
    A Randomized Controlled Multicenter Clinical Study on the Safety and Efficacy of Transcatheter Arterial Chemoembolization Combined with Apatinib and Camrelizumab versus Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Recurrent Hepatocellular Carcinoma (ChiCTR2400091246)
    P4, N=128, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P4 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    1m
    Drug-eluting Beads Transcatheter Arterial Chemoembolization Plus Adebrelimab and Apatinib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (TACT-01): A Single-arm, Exploratory Trial (ChiCTR2400090184)
    P2, N=31, Not yet recruiting, The First Hospital of China Medical University; The First Hospital of China Medical University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiTan (rivoceranib) • Ariely (adebrelimab)
    1m
    Efficacy and Safety of GP Chemotherapy Regimen Plus Camrelizumab Combined with Apatinib as First-Line Treatment for Nasopharyngeal Carcinoma with Liver Metastasis: A Prospective, Single-Arm, Open-Label Phase II Clinical Study (ChiCTR2400089020)
    P2, N=33, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    1m
    An open-label and multicenter Phase Ⅰ Clinical Study to Evaluate the Safety and Efficacy of SYS6010 in combination with Enlonstobart and Simmitinib in patients with advanced esophageal cancer (ChiCTR2400089300)
    P1, N=60, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology; The First Affiliated Hospital of Henan University of Science and Technolo
    New P1 trial • Combination therapy • Metastases
    |
    Enshuxing (enlonstobart) • simmitinib (SYHA1817)
    1m
    Safety & Efficacy of Genakumab in Patients With Frequent Flares (clinicaltrials.gov)
    P3, N=302, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Jul 2024 --> Apr 2024 | Trial primary completion date: Oct 2023 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CRP (C-reactive protein)
    |
    genakumab (Gensci048)
    1m
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    1m
    Gensci 048-202: Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy (clinicaltrials.gov)
    P2, N=106, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> May 2024
    Trial completion • Trial completion date
    |
    genakumab (Gensci048)
    1m
    A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer (clinicaltrials.gov)
    P3, N=885, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • oxaliplatin
    1m
    Gensci 048-203: Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare (clinicaltrials.gov)
    P2, N=106, Completed, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Completed
    Trial completion
    |
    genakumab (Gensci048)
    1m
    A Bioequivalence Study of Two Different Dosage Form of Genakumab (clinicaltrials.gov)
    P1, N=178, Active, not recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    genakumab (Gensci048)
    1m
    Design, synthesis, and evaluation of novel thiadiazole derivatives as potent VEGFR-2 inhibitors: a comprehensive in vitro and in silico study. (PubMed, RSC Adv)
    Compound 20b presents as a promising anti-proliferative agent targeting VEGFR-2. Also, this comprehensive investigation underscores the potential of 2,3-dihydro-1,3,4-thiadiazole derivatives as promising candidates for further development in anti-cancer research.
    Preclinical • Journal
    |
    CASP8 (Caspase 8) • CASP9 (Caspase 9)
    |
    sorafenib
    1m
    Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center
    New P1 trial • Combination therapy
    |
    albumin-bound paclitaxel • Cyramza (ramucirumab)
    1m
    Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. (PubMed, Cancer Sci)
    The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.
    Journal • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    2ms
    Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. (PubMed, World J Clin Oncol)
    Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • HER-2 amplification + PD-L1 expression • HER-2 positive + HER-2 overexpression
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • AiTan (rivoceranib) • Aidixi (disitamab vedotin) • anbenitamab (KN026)
    2ms
    RAMOSE: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Xiuning Le | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab)
    2ms
    STRIKE: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (clinicaltrials.gov)
    P3, N=1040, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    Keytruda (pembrolizumab) • Fotivda (tivozanib)
    2ms
    Efficacy, Safety, and Influence on Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1 Positive NSCLC: A Phase 2 Trial (EAST ENERGY). (PubMed, Clin Cancer Res)
    This new neoadjuvant combination of pembrolizumab plus ramucirumab was feasible and anti-VEGF agents may enhance the effects of ICIs.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)